New target for prostate cancer therapy
(Medical Xpress) -- Researchers at Imperial College London have discovered a molecule that plays an important role in driving prostate cancer growth, and could be a target for new therapies.
About 36,000 men are diagnosed with prostate cancer each year in the UK, making it the most common cancer in men. The cancer depends on male hormones to progress, as these hormones stimulate the cancer cells to divide, enabling the tumour to grow.
The new study, published in Human Molecular Genetics, found that male hormones increase the production of a molecule called miR-27a in prostate cancer cells in the laboratory, and that this molecule stimulates the cells to grow. An inhibitor of miR-27a halved the growth rate of prostate cancer cells, suggesting that such a molecule might have therapeutic potential.
miR-27a belongs to a class of molecules called microRNAs short strands of genetic material which are increasingly understood to play an important role in regulating gene activity. MicroRNAs are appealing as therapeutic targets since compared with proteins, it is much easier to design and synthesise inhibitory molecules that can get into cells easily. Another microRNA inhibitor is already being tested in humans in combination with chemotherapy for prostate cancer.
This is a promising first step towards a possible new therapy, but there are many hurdles to overcome first, said Claire Fletcher, the studys first author, who is studying for a PhD in Dr Charlotte Bevans lab in the Department of Surgery and Cancer at Imperial.
MicroRNAs have only been known about for the last 10 years, but were now realising how important they are in regulating which genetic messages are read and thus which proteins are produced. This study shows that miR-27a is an important intermediary that links hormones with prostate cancer growth. Weve demonstrated that inhibiting this molecule can suppress prostate cancer growth in the lab. The next step is to test that concept in an animal model. It will be several years at least before we can test any new treatments in humans.
The subset of genes that are turned on in a cell determine how the cell behaves. If a gene is switched on, its code is copied onto a messenger molecule and the message is translated to make a protein, which carries out a specific function. MicroRNAs work by interfering with the messenger so that the protein does not get made.
Each microRNA can regulate many genes. The new study found that one of the targets of miR-27a is a tumour suppressor called prohibitin, which the Imperial team previously discovered is a regulator of prostate cancer growth.
The research was funded by the Medical Research Council, Cancer Research UK and Prostate Cancer UK.
More information: CE Fletcher et al. Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer. Human Molecular Genetics (2012) 21 (14):3112-3127.doi: 10.1093/hmg/dds139
Journal reference: Human Molecular Genetics
Provided by Imperial College London
- Scientists find key protein that suppresses prostate cancer growth in the laboratory Jan 31, 2011 | not rated yet | 0
- Prostate cancer early warning protein detected May 31, 2012 | not rated yet | 0
- Scientists discover potential new target for prostate cancer treatment Feb 13, 2011 | not rated yet | 0
- Researchers ID molecule linked to aggressive cancer growth, spread Nov 13, 2008 | not rated yet | 0
- MicroRNA suppresses prostate cancer stem cells and metastasis Jan 16, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
16 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...
Cancer 4 hours ago | not rated yet | 0
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Cancer 5 hours ago | not rated yet | 0
A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...
Cancer 6 hours ago | not rated yet | 0
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer 7 hours ago | not rated yet | 0
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer 9 hours ago | not rated yet | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
11 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
9 hours ago | 4.9 / 5 (9) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
5 hours ago | 3 / 5 (2) | 0
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
6 hours ago | 5 / 5 (3) | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
11 hours ago | 4.4 / 5 (5) | 0 |
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
7 hours ago | not rated yet | 0 |